{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:06:08Z","timestamp":1753887968630,"version":"3.41.2"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":150,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BioMed Research International"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. Accessibility of full dose daily of tenofovir disoproxil fumarate (TDF) is limited in Madagascar with an estimated cost well above the purchasing power of Malagasy population. <jats:italic>Objective<\/jats:italic>. The study is aimed at evaluating the efficacy and safety of low\u2010dose tenofovir for the treatment of chronic hepatitis B (CHB). <jats:italic>Methods<\/jats:italic>. This prospective cohort study from January 2018 to December 2020 was conducted in the Department of Hepato\u2010Gastroenterology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar. The patients enrolled in the study received low dose of TDF 900\u2009mg\/week (300\u2009mg daily, three days per week). <jats:italic>Results<\/jats:italic>. A total of 45 patients (male\/female: 31\/14) were included. The mean age was 45.1 \u00b1 11.5 years. Fifteen patients were nucleos(t)ide (NA)\u2010na\u00efve, and 30 patients had prior NA therapy (NA\u2010experienced). Thirty patients were HBeAg positive. A complete virological response (CVR) was achieved in 36\/45 patients (80%) at 3 months, 41\/45 (91.1%) at 6 months, and 43\/45 (95.6%) at 12 months. High viral load at baseline was negative predictive factor of CVR at 3 months (HR: 0.14; 95% CI: 0.022\u20130.92; <jats:italic>p<\/jats:italic>: 0.041). There was no significant difference in response between HBeAg\u2010positive and HBeAg\u2010negative patients, NA\u2010na\u00efve and NA\u2010experienced patients, and cirrhotic and noncirrhotic patients. Low dose of tenofovir was well tolerated. Ten patients (22.22%) had mild side effects. Mild renal failure was observed in 3 patients (6.7%) during follow\u2010up. <jats:italic>Conclusion<\/jats:italic>. Low dose of tenofovir is effective, safe, and well tolerated in a Malagasy population sample. These results still require verification in a large population.<\/jats:p>","DOI":"10.1155\/2022\/1654620","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:50:42Z","timestamp":1654044642000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Low Dose of Tenofovir Disoproxil Fumarate in Malagasy Patients with Chronic Hepatitis B"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5751-0373","authenticated-orcid":false,"given":"Chantelli Iamblaudiot","family":"Razafindrazoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-3799","authenticated-orcid":false,"given":"Tovo Harimanana","family":"Rabenjanahary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-773X","authenticated-orcid":false,"given":"Andry Lalaina Rin\u00e0","family":"Rakotozafindrabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9687-9846","authenticated-orcid":false,"given":"Sedera Radoniaina","family":"Rakotondrasoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4260-9485","authenticated-orcid":false,"given":"Nitah Harivony","family":"Randriamifidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjaramalala Sitraka","family":"Rasolonjatovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-4941","authenticated-orcid":false,"given":"Soloniaina H\u00e9lio","family":"Razafimahefa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rado Manitrala","family":"Ramanampamonjy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"e_1_2_14_1_2","unstructured":"World Health Organization Hepatitis B key facts-July 2021 https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i1.48"},{"key":"e_1_2_14_3_2","first-page":"50","article-title":"Infection par le virus de l\u2019h\u00e9patite B un probl\u00e8me de sant\u00e9 publique \u00e0 Madagascar","volume":"66","author":"Migliani R.","year":"2000","journal-title":"Archives de l'Institut Pasteur de Madagascar"},{"key":"e_1_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.672972"},{"key":"e_1_2_14_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0399-8320(07)89385-7"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i30.4096"},{"key":"e_1_2_14_7_2","article-title":"0434: Low dose tenofovir disoproxil fumarate improves kidney function and sustains virologic suppression in renally compromised chronic hepatitis B patients (abstract)","volume":"68","author":"Sem Lieng K.","year":"2018","journal-title":"Hepatology"},{"key":"e_1_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.4236\/ojgas.2018.86024"},{"key":"e_1_2_14_9_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i18.5524"},{"key":"e_1_2_14_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-4027-8"},{"key":"e_1_2_14_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2015.10.005"},{"key":"e_1_2_14_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.028"},{"key":"e_1_2_14_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04454-14"},{"key":"e_1_2_14_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-008-9045-6"},{"key":"e_1_2_14_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24201"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.04.007"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.157558"},{"key":"e_1_2_14_18_2","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.15(5)2015.25749"},{"key":"e_1_2_14_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05489-7"},{"key":"e_1_2_14_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15499"},{"key":"e_1_2_14_21_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.10.1212"},{"key":"e_1_2_14_22_2","first-page":"100","article-title":"\u00c9valuation du traitement de l\u2019h\u00e9patite Virale B par les analogues nucl\u00e9otidiques \u00e0 Brazzaville","volume":"21","author":"Ahoui Apendi C.","year":"2020","journal-title":"Health Sciences and Disease"}],"container-title":["BioMed Research International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2022\/1654620.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2022\/1654620.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2022\/1654620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:36:35Z","timestamp":1735659395000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2022\/1654620"}},"subtitle":[],"editor":[{"given":"Haruki","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1155\/2022\/1654620"],"URL":"https:\/\/doi.org\/10.1155\/2022\/1654620","archive":["Portico"],"relation":{},"ISSN":["2314-6133","2314-6141"],"issn-type":[{"type":"print","value":"2314-6133"},{"type":"electronic","value":"2314-6141"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2021-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1654620"}}